Earnings results for Vaxcyte (NASDAQ:PCVX)
Vaxcyte, Inc. is estimated to report earnings on 03/25/2021. The upcoming earnings date is derived from an algorithm based on a company’s historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 1 analysts’ forecasts, the consensus EPS forecast for the quarter is $-0.48.
Analyst Opinion on Vaxcyte (NASDAQ:PCVX)
4 Wall Street analysts have issued ratings and price targets for Vaxcyte in the last 12 months. Their average twelve-month price target is $48.00, predicting that the stock has a possible upside of 110.62%. The high price target for PCVX is $55.00 and the low price target for PCVX is $37.00. There are currently 4 buy ratings for the stock, resulting in a consensus rating of “Buy.”
Vaxcyte has received a consensus rating of Buy. The company’s average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings. According to analysts’ consensus price target of $48.00, Vaxcyte has a forecasted upside of 110.6% from its current price of $22.79. Vaxcyte has received no research coverage in the past 90 days.
Dividend Strength: Vaxcyte (NASDAQ:PCVX)
Vaxcyte does not currently pay a dividend. Vaxcyte does not have a long track record of dividend growth.
Insiders buying/selling: Vaxcyte (NASDAQ:PCVX)
In the past three months, Vaxcyte insiders have sold more of their company’s stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $13,519,334.00 in company stock. 74.08% of the stock of Vaxcyte is held by institutions. High institutional ownership can be a signal of strong market trust in this company.
Earnings and Valuation of Vaxcyte (NASDAQ:PCVX
Earnings for Vaxcyte are expected to grow in the coming year, from ($6.20) to ($1.52) per share.
More latest stories: here